AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Watch out for these foods—they could trigger allergic reactions on your skin and cause various other discomforts.

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...

In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV) In multiple preclinical models ...

Brittany Lancellotti, DVM, DACVD, talks about available treatment options for flea allergies, environmental allergies, and ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

Brittany Lancellotti, DVM, DACVD, offered ways veterinarians can help reduce caregiver burden in clients in an interview at the 2024 Fetch Long Beach conference ...

The following is a summary of “Continuum of light sensitivity in atopic dermatitis: A retrospective analysis of 139 cases in ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether ...